This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Cardiovascular Diabetology
FEBRUARY 6, 2025
The rising prevalence of obesity and its association with heart failure with preserved ejection fraction (HFpEF) highlight an urgent need for a diagnostic approach tailored to this population. Diagnosing HFpEF.
Cardiovascular Diabetology
AUGUST 13, 2024
Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred.
Science Daily - Heart Disease
AUGUST 1, 2024
A new small study has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).
117 
American College of Cardiology
APRIL 6, 2024
The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).
Med Page Today
NOVEMBER 16, 2024
(MedPage Today) -- CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. Incident.
Med Page Today
OCTOBER 2, 2024
(MedPage Today) -- The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based on the small HuMain-HFpEF trial. After 19 weeks on daily.
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
Cardiovascular Diabetology
MARCH 21, 2025
Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.
Journal of Clinical Investigation - Cardiology
DECEMBER 15, 2023
Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.
JAMA Cardiology
MARCH 11, 2025
This randomized clinical trial evaluates if HU6, a controlled metabolic accelerator, reduces body weight, improves body composition, and increases exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).
American College of Cardiology
NOVEMBER 16, 2024
The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
American College of Cardiology
NOVEMBER 16, 2024
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
American College of Cardiology
JULY 16, 2024
For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?
American College of Cardiology
JUNE 24, 2024
Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)
American College of Cardiology
AUGUST 26, 2024
The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′.
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
American College of Cardiology
JANUARY 15, 2025
Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF.
American College of Cardiology
SEPTEMBER 26, 2024
Does semaglutide efficacy vary with baseline diuretic use and does semaglutide change diuretic dose in patients with heart failure with preserved ejection fraction (HFpEF)?
JAMA Cardiology
NOVEMBER 15, 2024
In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.
Journal of the American Heart Association
MARCH 13, 2025
BackgroundHeart failure with preserved ejection fraction (HFpEF) constitutes more than half of all HF but has few effective therapies. Journal of the American Heart Association, Ahead of Print. Recent human myocardial transcriptomics and metabolomics have identified major differences between HFpEF and controls.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
Circulation
JANUARY 22, 2025
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Circulation, Ahead of Print.
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.
Cardiovascular Diabetology
SEPTEMBER 10, 2024
Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.
Circulation: Heart Failure
JANUARY 28, 2025
BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. The generated organoids were then subjected to HFpEF-associated, comorbidity-inspired conditions, such as hypertension, diabetes, and obesity-related inflammation.
American College of Cardiology
JULY 1, 2024
What is the effect of semaglutide compared with placebo on N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels in patients with heart failure and preserved ejection fraction (HFpEF)?
American College of Cardiology
DECEMBER 13, 2023
Obesity is quite common in patients suffering from heart failure with preserved ejection fraction (HFpEF). Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to cause weight loss and reduce cardiovascular events in patients with obesity.
Journal of the American Heart Association
FEBRUARY 14, 2024
Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
The New England Journal of Medicine
NOVEMBER 15, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
American College of Cardiology
MAY 20, 2024
The GLP1RA semaglutide reduces N-terminal pro-brain natriuretic peptide (NTproBNP) in patients with obesity-related HF with preserved ejection fraction (HFpEF), and it may hold greater benefits for patients who start treatment with a higher baseline NTproBNP.
Circulation
SEPTEMBER 2, 2024
Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.
Clinical Trial Results
NOVEMBER 16, 2024
Disclosures: TBD
Circulation: Heart Failure
SEPTEMBER 12, 2023
BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers.
40 European Journal of Heart Failure
DECEMBER 13, 2023
Association between epicardial adipose tissue (EAT) and cardiac dysfunction in severe obesity. Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain.
40 Clinical Trial Results
SEPTEMBER 1, 2024
Disclosures: TBD ESC 2024_Rabea_Asleh Download
Circulation
APRIL 1, 2025
BACKGROUND:Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Circulation, Ahead of Print. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells.
European Journal of Heart Failure
MARCH 19, 2025
Abstract Aims Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes.
Circulation
NOVEMBER 11, 2024
Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. l) for 8 weeks.
Circulation
NOVEMBER 11, 2024
The CardioMEMS PA (pulmonary artery) sensor allows remote pulmonary artery diastolic (PAD) pressure monitoring to adjust diuresis in heart failure with preserved ejection fraction (HFpEF).
DAIC
FEBRUARY 29, 2024
ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)
103 The New England Journal of Medicine
NOVEMBER 15, 2024
In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo.
American Heart News - Heart News
NOVEMBER 16, 2024
called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide for an average of 2 years had. Research Highlights: In an international trial of 713 adults in nine countries including the U.S.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content